newsfilter
← Latest News
GlobeNewswire·

Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study

The Company signed contracts for the manufacturing of registration batches in view of the potential application for Emergency Use Authorization to FDA and/or Conditional Marketing Authorization to EMA The 155th patient has completed treatment in Part 2